Navigation Links
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
Date:10/8/2007

NEW YORK, Oct. 8 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2008 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 16, 2007. Later that day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff, President and Chief Operating Officer and Frank Perier, Senior Vice President and Chief Financial Officer, will discuss the financial results and relevant company and industry topics. The conference call will be webcast live beginning at 10:00 AM EDT on the Company's website http://www.frx.com and also on the website http://www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until October 31, 2007 at both websites and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291 (international investors), ID 19769552.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Forest Laboratories and Its Products

Forest Laboratories (http://www.frx.com) is a U.S.-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate and severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

*Benicar is a registered trademark of Daiichi Sankyo, and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird flu threat ruled out: Karnataka Forest Department
2. Will The Tropical Forests Survive The Deforestation Scenario?
3. Higher Health Cost Due to Forest Fires
4. Forest Fire Affects Singapores Air Quality
5. India to Protect Its Forests With the Aid of Austrian NGO
6. Human Induced Nitrogen Deposition Increasing Carbon Sequestration in Forests
7. Deforestation Plays a Critical Role in Climate Change: Study
8. China Unveils Green Plan to Revert Farmland to Forest
9. Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming
10. International Conference On Malaria - Laveran To Genomics
11. African Conference to Combat AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... FCPX LUT ... Editors can quickly and easily add washed color grades to footage. A LUT ... LUT changes every pixel’s color to the corresponding color indicated by the table. This ...
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon running has surged ... country. , Outdoor running increases exposure to ultraviolet radiation, a carcinogen that promotes ... melanoma, and only half may be adequately protecting themselves with proper clothing and ...
(Date:8/21/2017)... ... ... PIXACORE , an independent full-service agency with a decade of experience ... year by MM&M. , This is the first time PIXACORE has made the Top ... PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic transformation. ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... services business of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar partnership ... affected by post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over the ...
(Date:8/20/2017)... ... August 20, 2017 , ... ... HIPAA ComplyPAK™ Compliance Management System has assisted multiple clients in successfully passing ... Accountants, Service Organization Control Level 2 (AICPA SOC Level 2), and State Data ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... 2017 Three Tru-D SmartUVC robots have arrived at ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 ... environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at ... "Although the BAACH has a very low ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... Ind., July 27, 2017  Zimmer Biomet Holdings, Inc. ... quarter ended June 30, 2017.  The Company reported second ... 1.1% over the prior year period, and an increase ... 240 basis points of contribution from the LDR Holding ... the second quarter of 2016, or 0.3% on a ...
Breaking Medicine Technology: